Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
4 of 4 strong
The short version
Kwality Pharmaceuticals targets around INR 700+ crores revenue in FY27 with 26-27% EBITDA margin. Fy27 revenue guidance: INR700+ crores with 26%-27% EBITDA margins.
From Kwality Pharmaceuticals Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Kwality Pharmaceuticals targets around INR 700+ crores revenue in FY27 with 26-27% EBITDA margin.
- Anticipates 25%-30% year-on-year revenue growth through FY28 to FY30.
- Plans to achieve INR 1000 crores revenue by FY29 and INR 1300-1500 crores by FY30.
- Revenue mix expects 35-40% from generics, 15-20% oncology, 15-20% hormone (around INR 200 crores by FY30), and 15-30% biosimilars (up to 30% if Keytruda registered by FY30).
- Geographically, expects 40% sales from general facility, 35% LATAM, 15-20% MENA, 10-15% GCC, and 10-15% Europe (from FY28).
- India to become a significant market from FY30 after biosimilar clinical trial completions.
2 more points from Kwality Pharmaceuticals Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Kwality Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Kwality Pharmaceuticals plans a total capex of approximately INR185-190 crores.
- INR70 crores allocated to the hormone facility, expected to complete by November.
- INR50 crores allocated to oncology expansion, expected to complete by March next year.
- INR25-30 crores planned for bioequivalence (BE) studies.
- INR10-15 crores allocated for biosimilar R&D.
- INR20 crores set aside for working capital.
- Biological clinical trial capex of around INR150 crores planned spanning multiple fiscal years.
- Expansion in oncology facility to increase capacity by 45-50%.
- General facility expansion to add around 20% more capacity.
- Capex mainly to be spent between Q3 FY28 to Q4 FY29.
2 more points from Kwality Pharmaceuticals Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Kwality Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Kwality Pharmaceuticals Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Kwality Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹157 Cr, net profit ₹25 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Kwality Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Trident Lifeline Ltd (Q1 FY27)
Q1 FY26: ₹23.6 crores . Key investor presentation takeaways from Trident Lifeline Ltd's Q1 FY27 investor presentation — and how it ranks against sector peers.
- Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
- Wanbury Ltd (Q1 FY27)
Q4FY26 Revenue from Operations: ₹164.58 Crore . Key concall takeaways from Wanbury Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.
- Symbiotec Pharma (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹218.2 crores, up 7% YoY from ₹203.2 crores in Q1 FY26 (Page 9). Key concall takeaways from Symbiotec Pharmalab…
Arthneeti Pro · Annual
Kwality Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Kwality Pharmaceuticals Ltd Q1 FY27 results?
Kwality Pharmaceuticals targets around INR 700+ crores revenue in FY27 with 26-27% EBITDA margin. Fy27 revenue guidance: INR700+ crores with 26%-27% EBITDA margins.
What is Kwality Pharmaceuticals Ltd share price analysis?
Kwality Pharmaceuticals Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 39.1 with a market cap of ₹2,655 Cr. Investors should review the full earnings analysis for detailed insights.
Is Kwality Pharmaceuticals Ltd planning capital expenditure?
Kwality Pharmaceuticals plans a total capex of approximately INR185-190 crores.
Keep Kwality Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.